BACKGROUND: The current therapies for Crohn's disease (CD) are mainly focused on blockade of inflammation. Fibrosis remains one of the major complications of CD often leading to surgery, affecting patients' quality-of-life. AIM: To summarize the published data regarding the potential anti-fibrotic role of drugs commonly used in CD and the most effective anti-fibrotic drugs used in other diseases evaluating their potential use to treat intestinal fibrosis in CD. METHODS: A literature search was performed in the PubMed, Medline, Cochrane and EMBASE databases, considering in vitro, animal and human studies on fibrosis in inflammatory bowel disease and other similar chronic pathologies. RESULTS: Treatment of fibrosis in CD is limited to surgery or endoscopic dilatation, although some of the drugs currently used may have anti-fibrotic activity. In other diseases, anti-fibrotic agents are already used or are in preclinical or clinical trials. ACE inhibitors, Angiotensin Receptor Blockers, and HMG-CoA inhibitors merit further investigation in CD because of their role in preventing fibrosis in cardiovascular and renal diseases. CONCLUSIONS: Anti-fibrotic drugs are under evaluation or already used in clinical practice in other chronic inflammatory diseases. In CD, there is a great need for investigation into agents that may prevent, reduce or reverse intestinal fibrosis.
BACKGROUND: The current therapies for Crohn's disease (CD) are mainly focused on blockade of inflammation. Fibrosis remains one of the major complications of CD often leading to surgery, affecting patients' quality-of-life. AIM: To summarize the published data regarding the potential anti-fibrotic role of drugs commonly used in CD and the most effective anti-fibrotic drugs used in other diseases evaluating their potential use to treat intestinal fibrosis in CD. METHODS: A literature search was performed in the PubMed, Medline, Cochrane and EMBASE databases, considering in vitro, animal and human studies on fibrosis in inflammatory bowel disease and other similar chronic pathologies. RESULTS: Treatment of fibrosis in CD is limited to surgery or endoscopic dilatation, although some of the drugs currently used may have anti-fibrotic activity. In other diseases, anti-fibrotic agents are already used or are in preclinical or clinical trials. ACE inhibitors, Angiotensin Receptor Blockers, and HMG-CoA inhibitors merit further investigation in CD because of their role in preventing fibrosis in cardiovascular and renal diseases. CONCLUSIONS: Anti-fibrotic drugs are under evaluation or already used in clinical practice in other chronic inflammatory diseases. In CD, there is a great need for investigation into agents that may prevent, reduce or reverse intestinal fibrosis.
Authors: Keith W McLarren; Alexandra E Cole; Shelley B Weisser; Nicole S Voglmaier; Victoria S Conlin; Kevan Jacobson; Oana Popescu; Jean-Luc Boucher; Laura M Sly Journal: Am J Pathol Date: 2011-05-07 Impact factor: 4.307
Authors: Jalahalli M Siddesha; Emily M Nakada; Bethany R Mihavics; Sidra M Hoffman; Gurkiranjit K Rattu; Nicolas Chamberlain; Jonathon M Cahoon; Karolyn G Lahue; Nirav Daphtary; Minara Aliyeva; David G Chapman; Dhimant H Desai; Matthew E Poynter; Vikas Anathy Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-05-06 Impact factor: 5.464
Authors: Shengli Ding; Kristen L W Walton; Randall Eric Blue; Kirk K McNaughton; Kirk Macnaughton; Scott T Magness; Pauline Kay Lund Journal: PLoS One Date: 2012-08-03 Impact factor: 3.240